Please use this identifier to cite or link to this item:
Title: Neuromyelitis Optica Treatment Analysis of 36 Patients
Authors: Bichuetti, Denis Bernardi [UNIFESP]
Lobato de Oliveira, Enedina Maria [UNIFESP]
Oliveira, Daniel May [UNIFESP]
Souza, Nilton Amorin de [UNIFESP]
Gabbai, Alberto Alain [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Issue Date: 1-Sep-2010
Publisher: Amer Medical Assoc
Citation: Archives Of Neurology. Chicago: Amer Medical Assoc, v. 67, n. 9, p. 1131-1136, 2010.
Abstract: Objective: To analyze treatment response in Brazilian patients with neuromyelitis optica.Design: Retrospective review.Setting: Neuroimmunology Clinic of the Federal University of Sao Paulo, Sao Paulo, Brazil.Patients: Thirty-six patients with relapsing-remitting optic-spinal disease; long, extending spinal cord lesions; and brain magnetic resonance images not meeting Barkhof criteria for multiple sclerosis, thus fulfilling the 1999 and 2006 criteria for neuromyelitis optica. Patients were followed up from 1994 to 2007.Main Outcome Measures: Relapses and accumulation of disability.Results: Mean follow-up time was 47.2 months and mean age at onset was 32.3 years. Sixty-four treatments were implemented in 36 patients, which included interferon beta, methotrexate, cyclophosphamide, prednisone, and azathioprine solely or plus prednisone. Patients who were treated with azathioprine or azathioprine with prednisone had a reduction in the occurrence of relapses and Expanded Disability Severity Scale score stabilization, as opposed to patients who received other treatments. Of the 4 patients who died, only 1 had received azathioprine treatment.Conclusion: Azathioprine as monotherapy or with prednisone seems to have reduced the relapse frequency and halted disability progression in the majority of patients treated, with minor and manageable adverse effects.
ISSN: 0003-9942
Other Identifiers:
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.